Tottenham Acquisition I to merge with Clene Nanomedicine in a $542.5m deal.

Tottenham Acquisition I, a special purpose acquisition company, agreed to merge with Clene Nanomedicine, a clinical-stage biopharmaceutical company, in a $542.5m deal. Upon the closing of the transactions, Clene will be NASDAQ-listed under a new ticker symbol. "Clene is excited to partner with Tottenham in the creation of shareholder value. By creating the world's first public pure-play nanotherapeutic company, Clene is especially honored to bring forward the first neuroreparative therapy candidate to potentially improve neurological function across multiple sclerosis, Parkinson's disease, ALS, and many other neurological diseases with Clene's lead asset, CNM-Au8. Bioenergetic failure is a common element of many neurodegenerative diseases that we hope will soon be treated successfully with CNM-Au8. The combined company will also enable further clinical investigation of its second key asset, CNM-ZnAg, in two newly launched studies for the treatment of Covid-19," Rob Etherington, Clene President and CEO.